US-based drug maker Bristol Myers Squibb has opted out of Bengaluru-based pharmaceutical major Biocon’s project to develop oral forms of insulin. Also, US-based GSVlabs has formed a joint venture with Bennett, Coleman and Co. Ltd, through its strategic investment arm, Brand Capital, for an accelerator programme in India.
